



OPEN ACCESS

EDITED AND REVIEWED BY
Olivier Feron,
Université catholique de Louvain, Belgium

*CORRESPONDENCE

Yulin Feng
✉ fengyulin2003@126.com
Quan Wen
✉ qwen12@fudan.edu.cn

RECEIVED 22 October 2024
ACCEPTED 18 November 2024
PUBLISHED 03 December 2024

CITATION

Wu J, He X, Xiong Z, Shi L, Chen D, Feng Y and Wen Q (2024) Corrigendum: Bruceine H mediates EGFR-TKI drug persistence in NSCLC by Notch3-dependent β -catenin activating FOXO3a signaling. *Front. Oncol.* 14:1515205. doi: 10.3389/fonc.2024.1515205

COPYRIGHT

© 2024 Wu, He, Xiong, Shi, Chen, Feng and Wen. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Bruceine H mediates EGFR-TKI drug persistence in NSCLC by Notch3-dependent β -catenin activating FOXO3a signaling

Jiahui Wu¹, Xiao He², Ziwei Xiong¹, Lingyu Shi¹, Daofeng Chen³, Yulin Feng^{2*} and Quan Wen^{1*}

¹Pharmacy, Jiangxi University of Chinese Medicine, Jiangxi, China, ²National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi, China, ³Pharmacy, Fudan University of Pharmacy, Shanghai, China

KEYWORDS

bruceine H, Notch3 inhibitor, EGFR-TKI, acquired resistance, non-small cell lung cancer

A Corrigendum on

Bruceine H mediates EGFR-TKI drug persistence in NSCLC by Notch3-dependent β -catenin activating FOXO3a signaling

By Wu J, He X, Xiong Z, Shi L, Chen D, Feng Y and Wen Q (2022). *Front. Oncol.* 12:855603. doi: 10.3389/fonc.2022.855603

In the published article, there was an error in **Figure 2D** as published. During the image combination process, the images of BH Control 2 and 3 were not deleted but were erroneously labeled as BD Control and BH 4 μ M, respectively, resulting in an overall incorrect layout. The corrected **Figure 2D** and its caption “Matrigel invasion assays of A549 cells were measured” appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 2

Antitumor effects of BH and BD against non-small cell lung cancer (NSCLC) cell lines *in vitro*. (A) The proliferation of cells as well as the IC₅₀ was determined in A549 and PC-9 cells after 24 and 48 h. (B) Cell migration of A549 cells was detected by wound healing assay. (C, D) Transwell migration and Matrigel invasion assays of A549 cells were measured. (E) The apoptosis of A549 and PC-9 cells was measured using flow cytometry 48 h after treatment with BH. All experiments were independently conducted at least three times and showed representative data. “**” represents BH group vs. the Control group (**p < 0.01, ***p < 0.001).